Navigation Links
Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
Date:8/31/2009

BASKING RIDGE, N.J., Aug. 31 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that the results of a Phase 2a clinical trial of their lead product, the anticoagulant system REG1, were released at the European Society of Cardiology Congress in Barcelona, Spain. The results, detailed in a poster entitled, "First Clinical Application of an Actively Reversible Direct Acting Factor IXa inhibitor in Elective Percutaneous Intervention", were presented by Dr. Mauricio Cohen, lead investigator of the study from the University of Miami-Miller School of Medicine. The poster was presented on Sunday, August 30, 2009.

This was the first study to evaluate REG1 in a clinical setting involving percutaneous coronary intervention (PCI). REG1 is a two component system consisting of RB006, a direct FIXa inhibitor and RB007, the active, specific control agent for RB006. This phase 2a study (REVERSAL-PCI) was an open-label, randomized, multicenter study that evaluated feasibility and safety during elective PCI comparing the REG1 anticoagulant system with unfractionated heparin in patients with coronary artery disease. All 26 patients in the study received aspirin and clopidogrel as background therapy. The primary endpoint of the study was major bleeding within 48 hours. Important secondary endpoints were a composite of death, myocardial infarction or urgent target vessel revascularization within 14 days and pharmacodynamic measures. The three arms of the study were designed to measure both total and partial anticoagulant reversal, with all REG1 subjects undergoing planned early arterial catheter sheath removal.

The study demonstrated that the REG1 System enabled safe and effective PCI. All procedures were successfully completed in the REG1 cohorts with no signs of catheter or guidewire thrombosis. Coagula
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
2. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
3. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
4. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
5. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
6. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
7. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
8. Neurocrine Biosciences Presents Elagolix Data
9. SAFC Biosciences(R) and Vivalis Collaborate to Optimize Cell Culture Media for Vaccines Production
10. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
11. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 Celtaxsys, Inc., a ... including those with rare and orphan inflammatory disease indications, ... U.S. Food and Drug Administration (FDA) to begin a ... acebilustat (CTX-4430), in adult CF patients in the US. ... Europe will be filed soon after. ...
(Date:7/6/2015)... SAN FRANCISCO, Calif. , July 6, 2015 /PRNewswire/ ... global pharmaceutical company, and Oculeve, a development-stage medical device ... disease, today announced that they have entered into an ... all-cash transaction.  Under the terms of the agreement, Allergan ... and commercialization milestone payments related to Oculeve,s lead development ...
(Date:7/6/2015)... China Information Technology, Inc. (the "Company" or "CNIT") (Nasdaq ... exchange, and big data solutions in China ... mobile app for Healthcare One Pass, ushering in a ... The Company jointly hosted the launch ceremony with the ... News Net.   The mobile app for Healthcare ...
Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4
... hospitals scramble to adopt the patient-centered focus that is ... at improving healthcare in the U.S., LodgeNet Healthcare ... engagement solution that encourages patients to become educated, active ... to interact with patients throughout the entire continuum of ...
... EAST BRUNSWICK, N.J. and EDISON, N.J., June 8, ... today announced they had entered into a broad-based ... controlled release products. Under the terms of the ... develop and manufacture products for Amerigen to commercialize ...
Cached Medicine Technology:LodgeNet Healthcare's eSUITE Solution Empowers Patients to Participate in Their Care 2LodgeNet Healthcare's eSUITE Solution Empowers Patients to Participate in Their Care 3LodgeNet Healthcare's eSUITE Solution Empowers Patients to Participate in Their Care 4Amerigen Pharmaceuticals and AustarPharma Enter Into Collaboration Agreement for Generic Oral Controlled Release Products 2
(Date:7/6/2015)... ... ... Olive Fertility Centre is proud to announce that Olive medical director Dr. Jason ... department of Family Practice. , “This award is a real honour,” says Dr Hitkari. ... changing so rapidly and we are also developing new models of patient-centred care that ...
(Date:7/6/2015)... CA (PRWEB) , ... July 06, 2015 , ... Seedstock ... deliver the keynote address at the 4th Annual Seedstock Sustainable Agriculture Conference – “Innovation ... year’s conference , held at the University of California-San Diego, will explore solutions ...
(Date:7/6/2015)... Livonia, MI (PRWEB) , ... July 06, 2015 , ... ... Group has teamed up with Livonia Save Our Youth and announced a new charity ... young people in regards to alcohol and drug abuse. Livonia Save Our Youth is ...
(Date:7/6/2015)... ... July 06, 2015 , ... Orthopaedic & Spine ... 100th case using SpineFrontier’s® PedFuse® REmind® Screws. The operation took place on Tuesday, ... The procedure was an L5-S1 posterior lumbar interbody fusion on a 69 year ...
(Date:7/5/2015)... Boston, MA (PRWEB) , ... July 06, 2015 , ... ... Boston Triathlon. City Sports will co-produce two training clinics for first-time triathletes this summer ... two clinics will take place on Thursday, July 9, at 6:00 p.m. at the ...
Breaking Medicine News(10 mins):Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 3Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 4Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 2Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 3Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 3Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 2Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 3
... , , , REDMOND, ... meeting that seeks solely to personally enlighten and transform the people ... annual meeting under the vision of Chairman and CEO Dwayne ... memory care communities, Aegis Living is in the business of taking ...
... , WASHINGTON , Jan. ... announced that it has filed a motion for immediate relief ... Georgia from the imminent and serious threat of ... late yesterday, seeks appointment of a monitor who will set ...
... online resources, coping tips , FRIDAY, Jan. 29 (HealthDay ... for 75 percent of adult cancer patients, according to ... , Breakthrough cancer pain refers to sudden, temporary flares ... is taking pain medication. , "We,re not talking about ...
... when caught early. But in a third of cases, ... when cure is much less likely. , Quicker identification ... mathematical model developed by researchers at the Ohio State ... Richard J. Solove Research Institute., The model uses information ...
... Association of Physicists in Medicine (AAPM) has issued a statement ... New York Times yesterday and earlier in the week that ... last decade involving people undergoing radiation therapy. While it ... the statement acknowledges their gravity. It reads in part: "The ...
... 2010 Investigators from the International Center for Biomedicine ... Center for Bioinformatics of the Universidad de Talca, have ... astemizole, may be suitable for use as PET (positron ... detection of Alzheimer,s Disease. The study is published in ...
Cached Medicine News:Health News:Aegis Living's CEO Transforms Business As Usual One Employee At a Time 2Health News:Aegis Living's CEO Transforms Business As Usual One Employee At a Time 3Health News:Justice Department Files for Immediate Relief Regarding Conditions in Georgia's Hospitals 2Health News:Justice Department Files for Immediate Relief Regarding Conditions in Georgia's Hospitals 3Health News:Justice Department Files for Immediate Relief Regarding Conditions in Georgia's Hospitals 4Health News:Three-Fourths of Cancer Patients Have Severe Flares of Pain 2Health News:Three-Fourths of Cancer Patients Have Severe Flares of Pain 3Health News:Curing more cervical cancer cases may be in the math 2Health News:AAPM statement on quality radiation therapy 2Health News:Promising new neuroimaging techniques for early detection of Alzheimer's disease 2
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... Marlin' Cervical Orthosis ensures ... semirigid molded polyethylene anterior frame ... allows free air flow and ... facilitates height adjustment. For added ...
... Aspen® Cervical Collars improves patient compliance, ... costs. Adjusts to user's anatomy, wicks ... head weight to shoulders and upper ... Front and back airflow openings. Adjustable ...
... Designed with patient need and comfort ... Appliance) family of products effectively address ... The Chairback frame attachment provides optimal ... (LSO) provides superior support for patient ...
Medicine Products: